With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.13130-79-5,1-Bromoisoquinolin-3-amine,as a common compound, the synthetic route is as follows.
To a stirred solution of 3-amino-1-bromoisoquinoline (444 mg, 2.00 mmol) in anhydrous dimethylformamide (10 mL) was added sodium hydride (60%, unwashed, 96 mg, 2.4 mmol) in one portion. The mixture was stirred at 25 C. for 5 min before 2-bromoethyl ether (90%, 250 muL, 2.00 mmol) was added. The mixture was stirred further at 25 C. for 5 h and at 75 C. for 72 h before it was cooled to 25 C., quenched with saturated ammonium chloride solution and diluted with ethyl acetate. The organic layer was separated, washed with water and brine, dried over Na2SO4, filtered and concentrated. Purification of the residue on silica gel eluting with 0% to 70% ethyl acetate/hexanes afforded Cap-143, step a as a yellow solid (180 mg, 31%). Rt=1.75 min (Cond.-MS-WI); 90% homogenity index; LCMS: Anal. Calc. for [M+H]+ C13H4BrN2O: 293.03; found: 293.04.
13130-79-5, 13130-79-5 1-Bromoisoquinolin-3-amine 289845, aisoquinoline compound, is more and more widely used in various fields.
Reference£º
Patent; Bristol-Myers Squibb Company; US2009/233925; (2009); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem